Insider Selling: Twist Bioscience (NASDAQ:TWST) SVP Sells $34,774.72 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 1,084 shares of the stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $32.08, for a total transaction of $34,774.72. Following the transaction, the senior vice president directly owned 142,187 shares of the company’s stock, valued at approximately $4,561,358.96. This trade represents a 0.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Paula Green also recently made the following trade(s):

• On Thursday, October 30th, Paula Green sold 6,920 shares of Twist Bioscience stock. The stock was sold at an average price of $31.44, for a total transaction of $217,564.80.
• On Monday, October 6th, Paula Green sold 9,724 shares of Twist Bioscience stock. The stock was sold at an average price of $32.19, for a total transaction of $313,015.56.
• On Monday, September 22nd, Paula Green sold 295 shares of Twist Bioscience stock. The shares were sold at an average price of $27.56, for a total transaction of $8,130.20.
• On Monday, September 8th, Paula Green sold 892 shares of Twist Bioscience stock. The stock was sold at an average price of $25.76, for a total value of $22,977.92.

Twist Bioscience Trading Down 1.2%

TWST opened at $30.27 on Friday. Twist Bioscience Corporation has a 52 week low of $24.07 and a 52 week high of $55.33. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. The business has a fifty day simple moving average of $29.33 and a 200-day simple moving average of $31.70. The firm has a market cap of $1.83 billion, a P/E ratio of -20.88 and a beta of 2.43.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research report on Monday, August 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a report on Wednesday, October 8th. Evercore ISI cut their target price on shares of Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 7th. Barclays reduced their target price on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating on the stock in a report on Thursday, October 2nd. Finally, Stephens began coverage on shares of Twist Bioscience in a research note on Monday. They issued an “overweight” rating and a $41.00 price target for the company. Ten research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $47.80.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its position in shares of Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company’s stock valued at $29,000 after purchasing an additional 303 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Twist Bioscience by 70.6% during the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock worth $29,000 after purchasing an additional 442 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Twist Bioscience by 15.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company’s stock valued at $85,000 after buying an additional 302 shares during the last quarter. Geneos Wealth Management Inc. acquired a new stake in Twist Bioscience in the second quarter valued at $97,000. Finally, CWM LLC lifted its holdings in Twist Bioscience by 61.4% during the 3rd quarter. CWM LLC now owns 4,331 shares of the company’s stock worth $122,000 after buying an additional 1,648 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.